| Mothorwan | hetamine         | LIGALE | . Efforto |
|-----------|------------------|--------|-----------|
| Menigini  | 111(41/61111111) |        |           |

White, odorless, bitter-tasting crystalline powder that is easily dissolved in water or alcohol; can be ingested orally, intranasally, injected, or smoked

## **Health Effects**

Acute

Enhanced mood; increased heart rate, blood pressure, body temperature, energy and activity; decreased appetite; dry mouth; increased sexuality; jaw-clenching

Long-term

Addiction, memory loss; weight loss; impaired cognition; insomnia, anxiety, irritability, confusion, paranoia, aggression, mood disturbances, hallucinations, violent behavior; liver, kidney, lung damage; severe dental problems; cardiac and neurological damage; HIV, Hepatitis

Withdrawal symptoms

Depression, anxiety, fatigue, and intense craving for the drug.

## **Associated Special Vulnerabilities/Populations**

Pregnancy

Increased risk of premature birth, placental abruption, fetal growth retardation, and heart and brain abnormalities

## **Treatment options**

Medications

There are no FDA-approved medications to treat methamphetamine addiction.

Behavioral

Therapies

- Cognitive-behavioral therapy (CBT)
- Contingency management, or motivational incentives
- The matrix model
- 12-Step facilitation therapy

(For more information on these treatments, please see NIDA's <u>Principles of Drug Addiction Treatment: A Research-Based Guide - Behavioral Therapies.</u>)